Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

During the 31st APEC Economic Leaders' Meeting in Lima, Peru, this week, a milestone will be reached - the Chancay Port, controlled and invested by Chinese enterprises, is set to hold its operation ...

Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will ...

South Korea’s Alteogen (Kosdaq: 196170) has signed an exclusive licensing agreement with Japanese pharmaceutical company ...

Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Winners received prestigious award in recognition of latest innovations in advancement in life sciences ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...